1. Aguilar A, Gifre L, Ureña-Torres P, et al. Pathophysiology of bonedisease in chronic kidney disease: from basics to renal osteodystrophyand osteoporosis. Front Physiol. 2023;14:1177829.
2. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosisprevention, diagnosis, and therapy. J Am Med Assoc. 2001;285(6):785-795.
3. Abdalbary M, Sobh M, Elnagar S, et al. Management of osteoporosis inpatients with chronic kidney disease. Osteopor Int. 2022;33(11):2259-2274.
4. Panuccio V, Enia G, Tripepi R, et al. Pro-inflammatory cytokines andbone fractures in CKD patients. An exploratory single centre study.BMC Nephrol. 2012;13(1):1-6.
5. Meuwese CL, Snaedal S, Halbesma N, et al. Trimestral variations ofC-reactive protein, interleukin-6 and tumour necrosis factor-α aresimilarly associated with survival in haemodialysis patients. NephrolDial Transplant. 2011;26(4):1313-1318.
6. Mosca M, Nigro MC, Pagani R, De Giglio A, Di Federico A.Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal,and other solid tumors: immunotherapy and beyond. Biomolecules.2023;13(12):1803.
7. Ekinci F, Balcik OY, Oktay E, Erdogan AP. HALP Score as a newprognostic index in metastatic renal cell cancer. J Coll Physicians SurgPakistan. 2022;32(3):313-318.
8. Kocaoğlu S, Alatlı T. The efficiency of the HALP score and themodified HALP score in predicting mortality in patients with acuteheart failure presenting to the emergency department. J Coll PhysiciansSurg Pakistan. 2022;32(06):706-711.
9. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to preventionand treatment of osteoporosis. Osteopor Int. 2014;25(10):2359-2381.
10. Festuccia F, Jafari MT, Moioli A, et al. Safety and efficacy of denosumabin osteoporotic hemodialysed patients. J Nephrol. 2017;30(2):271-279.
11. Aslan B, Funda Sarı. Hemodiyaliz ve periton diyalizi yapan hastalardaosteoporoz sıklığı ve osteoporoz gelişmesini etkileyen faktörler.Akdeniz Tıp Derg. 2021;7(2):277-282.
12. Akchurin OM, Kaskel F. Update on inflammation in chronic kidneydisease. Blood Purif. 2015;39(1-3):84-92.
13. Duarte MP, Ribeiro HS, Neri SG, et al. Prevalence of low bonemineral density (T-score≤− 2.5) in the whole spectrum of chronickidney disease: a systematic review and meta-analysis. Osteopor Int.2023;34(3):467-477.
14. Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA.Differential expression of RANK, RANK-L, and osteoprotegerin bysynovial fluid neutrophils from patients with rheumatoid arthritis andby healthy human blood neutrophils. Arthritis Res Ther. 2007;9(2):R25.
15. Öztürk ZA, Yesil Y, Kuyumcu ME, et al. Inverse relationship betweenneutrophil lymphocyte ratio (NLR) and bone mineral density (BMD)in elderly people. Arch Gerontol Geriatr. 2013;57(1):81-85.
16. Lee SH, Ryu SY, Park J, Shin MH, Han MA, Choi SW. The relationshipof neutrophil-lymphocyte ratio and platelet-lymphocyte ratio withbone mineral density in Korean postmenopausal women. ChonnamMed J. 2019;55(3):150-155.
17. Koseoglu SB. Bone loss and platelet-to-lymphocyte ratio. BiomarkMed. 2017;11(1):5-10.
18. Yolaçan H, Guler, S. Inverse correlation between bone mineral densityand systemic immune inflammation index in postmenopausal Turkishwomen. Cureus. 2023;15(4):e37463.
19. Ban TH, Choi BS, Yoon SA, et al. Clinical significance of neutrophil-to-lymphocyte ratio on the risk of abdominal aortic calcification anddecreased bone mineral density in patients with end-stage kidneydisease. Plos One. 2023;18(10):0286612.
20. Pan H, Lin S. Association of hemoglobin, albumin, lymphocyte, andplatelet score with risk of cerebrovascular, cardiovascular, and all-cause mortality in the general population: results from the NHANES1999-2018. Front Endocrinol. 2023;14: 1173399.